Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease
Identifieur interne : 001983 ( Main/Exploration ); précédent : 001982; suivant : 001984Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease
Auteurs : Terecita D. Yule [États-Unis] ; Mark B. Roth [États-Unis] ; Kimberly Dreier [États-Unis] ; Anthony F. Johnson [États-Unis] ; Melissa Palmer-Densmore [États-Unis] ; Kris Simmons [États-Unis] ; Robert Fanton [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 1997.
English descriptors
- Teeft :
- Acute phase proteins, Acute phase reactants, Acute phase response, Assay, Canine, Canine neutrophils, Canine parvovirus, Canine parvovirus enteritis, Canine parvovirus type, Canine parvovirus vaccine, Cell count, Cell counts, Cell surface proteins, Clinical consequences, Clinical disease, Clinical manifestations, Clinical scores, Clinical signs, Control group, Control puppies, Control standards, Cpv3b challenge, Crypt cells, Cytometric, Cytometry, Days post challenge figure, Dose vaccine regimen, Elsevier science, Experimental challenge, Experimental infection, First vaccination, Flow buffer, Flow cytometric, Flow cytometric analysis, Flow cytometry, Immunol, Indirect effect, Individual animals, Inflammation, John wiley, Leukocyte, Leukocyte phenotypes, Leukocyte trafficking, Lymphocyte, Lymphopenia, Major capsid protein, Microtiter plates, Monoclonal antibodies, Natural infection, Natural infections, Neutropenia, Neutrophil, Neutrophil function, Neutrophilia, Nonvaccinated, Nonvaccinated controls, Observation period, Parvovirus, Parvovirus infection, Peripheral blood, Puppies seroconverted, Puppy, Second vaccination, Seropositive puppies, Serum amyloid, Significant deviation, Solid line, Solid lines, Third vaccination, Tissue antigens, Tissue damage, Titer, Total leukocyte count, Trafficking, Vaccinated, Vaccinated puppies, Vaccinates, Vaccination, Vaccine, Vaccine efficacy, Vascular endothelium, Virus infection, Virus recovery, Yule.
Abstract
Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.
Url:
DOI: 10.1016/S0264-410X(96)00232-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000804
- to stream Istex, to step Curation: 000771
- to stream Istex, to step Checkpoint: 000401
- to stream Main, to step Merge: 001998
- to stream Main, to step Curation: 001983
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title><author><name sortKey="Yule, Terecita D" sort="Yule, Terecita D" uniqKey="Yule T" first="Terecita D." last="Yule">Terecita D. Yule</name></author><author><name sortKey="Roth, Mark B" sort="Roth, Mark B" uniqKey="Roth M" first="Mark B." last="Roth">Mark B. Roth</name></author><author><name sortKey="Dreier, Kimberly" sort="Dreier, Kimberly" uniqKey="Dreier K" first="Kimberly" last="Dreier">Kimberly Dreier</name></author><author><name sortKey="Johnson, Anthony F" sort="Johnson, Anthony F" uniqKey="Johnson A" first="Anthony F." last="Johnson">Anthony F. Johnson</name></author><author><name sortKey="Palmer Densmore, Melissa" sort="Palmer Densmore, Melissa" uniqKey="Palmer Densmore M" first="Melissa" last="Palmer-Densmore">Melissa Palmer-Densmore</name></author><author><name sortKey="Simmons, Kris" sort="Simmons, Kris" uniqKey="Simmons K" first="Kris" last="Simmons">Kris Simmons</name></author><author><name sortKey="Fanton, Robert" sort="Fanton, Robert" uniqKey="Fanton R" first="Robert" last="Fanton">Robert Fanton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:ED82901CC45CF7E00C6B3215F1A3E36841490C1F</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1016/S0264-410X(96)00232-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-3H03FGMF-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000804</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000804</idno><idno type="wicri:Area/Istex/Curation">000771</idno><idno type="wicri:Area/Istex/Checkpoint">000401</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000401</idno><idno type="wicri:doubleKey">0264-410X:1997:Yule T:canine:parvovirus:vaccine</idno><idno type="wicri:Area/Main/Merge">001998</idno><idno type="wicri:Area/Main/Curation">001983</idno><idno type="wicri:Area/Main/Exploration">001983</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease</title><author><name sortKey="Yule, Terecita D" sort="Yule, Terecita D" uniqKey="Yule T" first="Terecita D." last="Yule">Terecita D. Yule</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Roth, Mark B" sort="Roth, Mark B" uniqKey="Roth M" first="Mark B." last="Roth">Mark B. Roth</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Dreier, Kimberly" sort="Dreier, Kimberly" uniqKey="Dreier K" first="Kimberly" last="Dreier">Kimberly Dreier</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Johnson, Anthony F" sort="Johnson, Anthony F" uniqKey="Johnson A" first="Anthony F." last="Johnson">Anthony F. Johnson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Palmer Densmore, Melissa" sort="Palmer Densmore, Melissa" uniqKey="Palmer Densmore M" first="Melissa" last="Palmer-Densmore">Melissa Palmer-Densmore</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Simmons, Kris" sort="Simmons, Kris" uniqKey="Simmons K" first="Kris" last="Simmons">Kris Simmons</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Fanton, Robert" sort="Fanton, Robert" uniqKey="Fanton R" first="Robert" last="Fanton">Robert Fanton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Central Research Division, Pfizer Inc., Eastern Point Road, Groton, CT 06340</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">6–7</biblScope><biblScope unit="page" from="720">720</biblScope><biblScope unit="page" to="729">729</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute phase proteins</term><term>Acute phase reactants</term><term>Acute phase response</term><term>Assay</term><term>Canine</term><term>Canine neutrophils</term><term>Canine parvovirus</term><term>Canine parvovirus enteritis</term><term>Canine parvovirus type</term><term>Canine parvovirus vaccine</term><term>Cell count</term><term>Cell counts</term><term>Cell surface proteins</term><term>Clinical consequences</term><term>Clinical disease</term><term>Clinical manifestations</term><term>Clinical scores</term><term>Clinical signs</term><term>Control group</term><term>Control puppies</term><term>Control standards</term><term>Cpv3b challenge</term><term>Crypt cells</term><term>Cytometric</term><term>Cytometry</term><term>Days post challenge figure</term><term>Dose vaccine regimen</term><term>Elsevier science</term><term>Experimental challenge</term><term>Experimental infection</term><term>First vaccination</term><term>Flow buffer</term><term>Flow cytometric</term><term>Flow cytometric analysis</term><term>Flow cytometry</term><term>Immunol</term><term>Indirect effect</term><term>Individual animals</term><term>Inflammation</term><term>John wiley</term><term>Leukocyte</term><term>Leukocyte phenotypes</term><term>Leukocyte trafficking</term><term>Lymphocyte</term><term>Lymphopenia</term><term>Major capsid protein</term><term>Microtiter plates</term><term>Monoclonal antibodies</term><term>Natural infection</term><term>Natural infections</term><term>Neutropenia</term><term>Neutrophil</term><term>Neutrophil function</term><term>Neutrophilia</term><term>Nonvaccinated</term><term>Nonvaccinated controls</term><term>Observation period</term><term>Parvovirus</term><term>Parvovirus infection</term><term>Peripheral blood</term><term>Puppies seroconverted</term><term>Puppy</term><term>Second vaccination</term><term>Seropositive puppies</term><term>Serum amyloid</term><term>Significant deviation</term><term>Solid line</term><term>Solid lines</term><term>Third vaccination</term><term>Tissue antigens</term><term>Tissue damage</term><term>Titer</term><term>Total leukocyte count</term><term>Trafficking</term><term>Vaccinated</term><term>Vaccinated puppies</term><term>Vaccinates</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine efficacy</term><term>Vascular endothelium</term><term>Virus infection</term><term>Virus recovery</term><term>Yule</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Inflammatory changes following infection are central to the clinical manifestation of disease. However, information regarding such changes in animal disease is limited. In canine parvovirus infected puppies we measured the levels of acute phase proteins and changes in leukocyte phenotypes and cell trafficking by flow cytometry. These parameters correlated with conventional assessment of clinical disease in a vaccine efficacy study. Seropositive (CPV-2) 6-week-old puppies given three doses of a CPV-2 containing vaccine developed significant antibody titers and remained healthy after experimental infection with CPV-2b. Unvaccinated controls developed clinical signs and shed virus. Importantly, acute phase proteins became elevated, and lymphopenia, neutropenia and modulation of neutrophil-CD4 were detected in controls but not in vaccinates.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li></region></list><tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Yule, Terecita D" sort="Yule, Terecita D" uniqKey="Yule T" first="Terecita D." last="Yule">Terecita D. Yule</name></region><name sortKey="Dreier, Kimberly" sort="Dreier, Kimberly" uniqKey="Dreier K" first="Kimberly" last="Dreier">Kimberly Dreier</name><name sortKey="Fanton, Robert" sort="Fanton, Robert" uniqKey="Fanton R" first="Robert" last="Fanton">Robert Fanton</name><name sortKey="Johnson, Anthony F" sort="Johnson, Anthony F" uniqKey="Johnson A" first="Anthony F." last="Johnson">Anthony F. Johnson</name><name sortKey="Palmer Densmore, Melissa" sort="Palmer Densmore, Melissa" uniqKey="Palmer Densmore M" first="Melissa" last="Palmer-Densmore">Melissa Palmer-Densmore</name><name sortKey="Roth, Mark B" sort="Roth, Mark B" uniqKey="Roth M" first="Mark B." last="Roth">Mark B. Roth</name><name sortKey="Simmons, Kris" sort="Simmons, Kris" uniqKey="Simmons K" first="Kris" last="Simmons">Kris Simmons</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001983 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001983 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:ED82901CC45CF7E00C6B3215F1A3E36841490C1F
|texte= Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease
}}
| This area was generated with Dilib version V0.6.33. |  |